A. Van Vreckem

Multicollinearity in prognostic factor analyses using the EORTC QLQ‐C30: identification and impact on model selection

G. Molenberghs, K. Van Steen, A. Bottomley, 2002, Statistics in medicine.

EORTC 10941: A phase II study of liarozole in postmenopausal patients with ‘Chemotherapy-Resistant’ or ‘Potentially Hormone Sensitive’ metastatic breast cancer

J. Klijn, M. Piccart, R. Paridaens, 2000, Breast Cancer Research and Treatment.

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.

M. van Glabbeke, J. Klijn, M. Nooij, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.

M. J. van de Vijver, D. Larsimont, M. Piccart, 2000, Clinical breast cancer.

Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.

J. Baselga, E. Felip, J. Albanell, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Pharmacokinetic and Pharmacodynamic Study of the Farnesyl Transferase Inhibitor BMS-214662 in Combination with Cisplatin in Patients with Advanced Solid Tumors

H. Mackay, J. Verweij, R. Hoekstra, 2004, Clinical Cancer Research.

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.

J. Klijn, M. Piccart, R. Paridaens, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.

J. Klijn, R. Paridaens, M. Piccart-Gebhart, 1996, Seminars in oncology.